Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.
Journal Information
Full Title: Postepy Dermatol Alergol
Abbreviation: Postepy Dermatol Alergol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict of interest Joanna Narbutt and Aleksandra Lesiak served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by: Novartis, AbbVie, Eli Lilly, Sandoz, Leo Pharma, Janssen, Sanofi. Other authors declare no conflict of interest."
Funding Disclosure
Evidence found in paper:
"The study was supported by research project of the Medical University of Lodz, Poland (number: 503/5-064-04/503-01)."
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025